Document is current

Any future updates will be listed below

Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib

Crossref DOI link: https://doi.org/10.1038/s41375-025-02824-y

Published Online: 2025-12-02

Published Print: 2026-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark